SBC Medical Group Holdings Inc. (NASDAQ: SBC), a Japanese owner and operator of aesthetic medical clinics, has concluded a transformative year marked by strategic initiatives aimed at solidifying its market leadership and fueling future growth. The company's efforts in 2025 focused on expanding its footprint, optimizing pricing, and entering new international markets, positioning it to capitalize on rising demand in the aesthetic medicine sector.
As of September 30, 2025, SBC Medical operated 258 franchise locations, a 15% year-over-year increase. The company also revised its pricing strategy, resulting in a 5% sequential increase in average revenue per customer in the third quarter of 2025. This improvement was driven by pricing optimization and a shift toward higher-revenue-generating customers through its multi-brand approach. New services, including plastic surgery and infertility treatments, were introduced across its franchise network, further differentiating SBC from competitors.
International expansion was a key theme in 2025, with SBC entering markets in Singapore and Thailand. In early 2026, the company announced its first U.S. expansion. Domestically, SBC launched two new brands: "Neo Skin Clinic" and "Hada no Aozora Clinic" in Tokyo. The latter employs a hybrid dermatology model that combines insurance-covered general dermatology with private-pay aesthetic treatments. Additionally, SBC acquired MB Career Lounge Co. Ltd., a provider of management support services for medical institutions, and Waqoo, a related subsidiary, to accelerate research and development in areas such as AGA and orthopedics.
Financially, SBC Medical reported a significant improvement in net profit for the third quarter of 2025, reflecting a return to a more typical cost structure after IPO-related expenses. Average revenue per visit rose 5% sequentially to $298, and the company maintained a high repeat rate of 72%. The company's stock buyback program, announced in spring 2025, authorized up to $5 million in share repurchases, underscoring management's confidence in the company's growth trajectory.
Inclusion in the Russell 3000 Index during 2025 increased SBC Medical's visibility among institutional and individual investors. The Russell indexes are widely used as benchmarks, with approximately $18.1 trillion in assets benchmarked globally. SBC Medical's addition to the index opens the door to a broader investor base, particularly those invested in index funds and ETFs tracking the Russell indexes.
SBC Medical also focused on capturing cosmetic tourism, particularly from Chinese consumers visiting Japan for advanced procedures. The company hired Chinese-speaking staff, promoted services on Chinese social media platforms, and developed a dedicated app. Events and seminars in Shanghai were held to attract new customers. In Singapore, SBC expanded its collaboration with Aesthetic Healthcare Holdings Pte. Ltd., which operates multiple brands in the medical aesthetics industry. In Thailand, SBC signed an e-consulting agreement with BLEZ ASIA Co. Ltd., which operates over 20 pharmacies and clinics, to support a new dermatological clinic in Bangkok.
The global cosmetic surgery and procedure market, valued at $122.08 billion in 2022, is expected to grow at a compound annual growth rate of 14.7% from 2023 to 2030, according to industry reports. SBC Medical's strategic moves in 2025—including acquisitions, market entries, and brand launches—position the company to leverage this growth. With $125 million in cash at the start of the year, SBC Medical has the financial flexibility to pursue further opportunities. As the aesthetic medicine market in Japan heats up, driven by affluent Asian consumers, SBC Medical stands ready to meet demand and capitalize on its enhanced capabilities.
